Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

Richard W Joseph, Mark Cappel, Katherine Tzou, Sanjay Bagaria, Cheryl Gilstrap, Abhisek Swaika, Anokhi Jambusaria-Pahlajani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Checkpoint blockade inhibitors have revolutionized the treatment of metastatic melanoma. Despite the success of these agents in improving the overall survival of patients with metastatic melanoma, not all patients achieve clinical benefit, leaving room for improvement. The presence of cutaneous metastases in patients with metastatic melanoma provides the unique opportunity to treat the cutaneous lesions with a local modality while simultaneously treating systemic disease with systemic therapy. Herein, we describe the treatment of two patients with both in-transit and metastatic melanoma with the combination of the topical toll-like receptor 7 agonist imiquimod with systemic ipilimumab. Both patients appeared to have progressed and developed new cutaneous and systemic metastases while on single agent ipilimumab only to respond when started on topical imiquimod. Both patients tolerated the combination of imiquimod and ipilimumab without serious adverse events, and both patients had excellent clinical responses. These cases provide a proof of principle of the possibility of the combination of toll-like receptor 7 agonists with immune checkpoint blockade inhibitors.

Original languageEnglish (US)
Pages (from-to)409-412
Number of pages4
JournalMelanoma Research
Volume26
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

imiquimod
Melanoma
Toll-Like Receptor 7
Skin
Therapeutics
Neoplasm Metastasis
ipilimumab

Keywords

  • imiquimod
  • ipilimumab
  • melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. / Joseph, Richard W; Cappel, Mark; Tzou, Katherine; Bagaria, Sanjay; Gilstrap, Cheryl; Swaika, Abhisek; Jambusaria-Pahlajani, Anokhi.

In: Melanoma Research, Vol. 26, No. 4, 01.08.2016, p. 409-412.

Research output: Contribution to journalArticle

Joseph, RW, Cappel, M, Tzou, K, Bagaria, S, Gilstrap, C, Swaika, A & Jambusaria-Pahlajani, A 2016, 'Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod', Melanoma Research, vol. 26, no. 4, pp. 409-412. https://doi.org/10.1097/CMR.0000000000000247
Joseph, Richard W ; Cappel, Mark ; Tzou, Katherine ; Bagaria, Sanjay ; Gilstrap, Cheryl ; Swaika, Abhisek ; Jambusaria-Pahlajani, Anokhi. / Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. In: Melanoma Research. 2016 ; Vol. 26, No. 4. pp. 409-412.
@article{edfc8e0dbef1423c91e8fdd68c4b8f5e,
title = "Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod",
abstract = "Checkpoint blockade inhibitors have revolutionized the treatment of metastatic melanoma. Despite the success of these agents in improving the overall survival of patients with metastatic melanoma, not all patients achieve clinical benefit, leaving room for improvement. The presence of cutaneous metastases in patients with metastatic melanoma provides the unique opportunity to treat the cutaneous lesions with a local modality while simultaneously treating systemic disease with systemic therapy. Herein, we describe the treatment of two patients with both in-transit and metastatic melanoma with the combination of the topical toll-like receptor 7 agonist imiquimod with systemic ipilimumab. Both patients appeared to have progressed and developed new cutaneous and systemic metastases while on single agent ipilimumab only to respond when started on topical imiquimod. Both patients tolerated the combination of imiquimod and ipilimumab without serious adverse events, and both patients had excellent clinical responses. These cases provide a proof of principle of the possibility of the combination of toll-like receptor 7 agonists with immune checkpoint blockade inhibitors.",
keywords = "imiquimod, ipilimumab, melanoma",
author = "Joseph, {Richard W} and Mark Cappel and Katherine Tzou and Sanjay Bagaria and Cheryl Gilstrap and Abhisek Swaika and Anokhi Jambusaria-Pahlajani",
year = "2016",
month = "8",
day = "1",
doi = "10.1097/CMR.0000000000000247",
language = "English (US)",
volume = "26",
pages = "409--412",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

AU - Joseph, Richard W

AU - Cappel, Mark

AU - Tzou, Katherine

AU - Bagaria, Sanjay

AU - Gilstrap, Cheryl

AU - Swaika, Abhisek

AU - Jambusaria-Pahlajani, Anokhi

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Checkpoint blockade inhibitors have revolutionized the treatment of metastatic melanoma. Despite the success of these agents in improving the overall survival of patients with metastatic melanoma, not all patients achieve clinical benefit, leaving room for improvement. The presence of cutaneous metastases in patients with metastatic melanoma provides the unique opportunity to treat the cutaneous lesions with a local modality while simultaneously treating systemic disease with systemic therapy. Herein, we describe the treatment of two patients with both in-transit and metastatic melanoma with the combination of the topical toll-like receptor 7 agonist imiquimod with systemic ipilimumab. Both patients appeared to have progressed and developed new cutaneous and systemic metastases while on single agent ipilimumab only to respond when started on topical imiquimod. Both patients tolerated the combination of imiquimod and ipilimumab without serious adverse events, and both patients had excellent clinical responses. These cases provide a proof of principle of the possibility of the combination of toll-like receptor 7 agonists with immune checkpoint blockade inhibitors.

AB - Checkpoint blockade inhibitors have revolutionized the treatment of metastatic melanoma. Despite the success of these agents in improving the overall survival of patients with metastatic melanoma, not all patients achieve clinical benefit, leaving room for improvement. The presence of cutaneous metastases in patients with metastatic melanoma provides the unique opportunity to treat the cutaneous lesions with a local modality while simultaneously treating systemic disease with systemic therapy. Herein, we describe the treatment of two patients with both in-transit and metastatic melanoma with the combination of the topical toll-like receptor 7 agonist imiquimod with systemic ipilimumab. Both patients appeared to have progressed and developed new cutaneous and systemic metastases while on single agent ipilimumab only to respond when started on topical imiquimod. Both patients tolerated the combination of imiquimod and ipilimumab without serious adverse events, and both patients had excellent clinical responses. These cases provide a proof of principle of the possibility of the combination of toll-like receptor 7 agonists with immune checkpoint blockade inhibitors.

KW - imiquimod

KW - ipilimumab

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=84978055835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978055835&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000247

DO - 10.1097/CMR.0000000000000247

M3 - Article

C2 - 27138458

AN - SCOPUS:84978055835

VL - 26

SP - 409

EP - 412

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -